857035-29-1

Basic information

• Product Name: 2-CHLORO-3H-BENZIMIDAZOLE-5-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 2-CHLORO-3H-BENZIMIDAZOLE-5-CARBOXYLIC ACID ETHYL ESTER;ethyl 2-chloro-1H-benzo[d]iMidazole-6-carboxylate;2-Chloro-1H-benzimidazole-6-carboxylic acid ethyl ester
• CAS NO: 857035-29-1
• Molecular Formula: C₁₀H₉ClN₂O₂
• Molecular Weight: 224.64
• Mol File: 857035-29-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: 2-CHLORO-3H-BENZIMIDAZOLE-5-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-3H-BENZIMIDAZOLE-5-CARBOXYLIC ACID ETHYL ESTER(857035-29-1)
• EPA Substance Registry System: 2-CHLORO-3H-BENZIMIDAZOLE-5-CARBOXYLIC ACID ETHYL ESTER(857035-29-1)

Safety Data

• Hazardous Substances Data: 857035-29-1(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
2-Chloro-3H-benzimidazole-5-carboxylic acid ethyl ester is used as a chemical intermediate in the synthesis of various compounds. Its unique structure allows it to participate in multiple reactions, aiding in the production of a wide range of products.
Used in Laboratory Research:
In the field of laboratory research, 2-Chloro-3H-benzimidazole-5-carboxylic acid ethyl ester is employed as a catalyst to accelerate chemical reactions. Its complex structure enables it to facilitate or catalyze a variety of reactions, contributing to the advancement of scientific research and the development of new compounds.
Used in Pharmaceutical Industry:
2-Chloro-3H-benzimidazole-5-carboxylic acid ethyl ester is used as a building block in the development of pharmaceutical compounds. Its versatile structure makes it a valuable component in the synthesis of potential drug candidates, contributing to the discovery of new treatments and therapies.
Used in Chemical Reactions:
In chemical reactions, 2-Chloro-3H-benzimidazole-5-carboxylic acid ethyl ester is used to facilitate or participate in various processes. Its unique structure allows it to interact with other compounds, promoting the formation of desired products and enhancing the efficiency of the reaction.
Used in Material Science:
2-Chloro-3H-benzimidazole-5-carboxylic acid ethyl ester is utilized in material science for the development of new materials with specific properties. Its complex structure can contribute to the creation of materials with unique characteristics, such as improved stability, reactivity, or other desirable attributes.

Upstream product

• 634602-84-9 2-hydroxy-3H-benzoimidazole-5-carboxylic acid ethyl ester 

Downstream Products

• 857070-66-7 (2-chloro-3H-benzoimidazol-5-yl)methanol 
• 1009646-55-2 2-[(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)amino]-3H-benzoimidazole-5-carboxylic acid ethyl ester 
• 1009646-67-6 2-phenethylamino-3H-benzoimidazole-5-carboxylic acid ethyl ester 
• 857070-67-8 [2-(3-morpholin-4-ylpropylamino)-3H-benzoimidazol-5-yl]methanol 
• 857035-30-4 2-(1-benzylpiperidin-4-ylamino)-3H-benzoimidazole-5-carboxylic acid ethyl ester 

Relevant articles and documents

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)

A preceding paper (Bonfanti et al. J. Med Chem. 2007, 50, 4572-4584) reported the optimization of the pharmacokinetic profile of substituted benzimidazoles by reducing their tissue retention. However, the modifications that were necessary to achieve this goal also led to a significant drop in anti-RSV activity. This paper describes a molecular modeling study followed by a lead optimization program that led to the recovery of the initial potent antiviral activity and the selection of TMC353121 as a clinical candidate.

5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION

The present invention concerns 5- or 6-substituted-benzimidazole derivatives having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I) a prodrug, N-oxide, addition salt, quaternary amine, metal complex or

MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION

The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I), a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereoc